{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:26:48Z","timestamp":1795012008036,"version":"4.9.1"},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"The Netherlands Organization for Health Research and Development","doi-asserted-by":"crossref","award":["848101001"],"award-info":[{"award-number":["848101001"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merck B.V."},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["GNT1176437"],"award-info":[{"award-number":["GNT1176437"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2009767"],"award-info":[{"award-number":["2009767"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>The ovarian response to gonadotropin stimulation varies widely among women, and could impact the probability of live birth as well as treatment risks. Many studies have evaluated the impact of different gonadotropin starting doses, mainly based on predictive variables like ovarian reserve tests (ORT) including anti-M\u00fcllerian hormone (AMH), antral follicle count (AFC), and basal follicle-stimulating hormone (bFSH). A Cochrane systematic review revealed that individualizing the gonadotropin starting dose does not affect efficacy in terms of ongoing pregnancy\/live birth rates, but may reduce treatment risks such as the development of ovarian hyperstimulation syndrome (OHSS). An individual patient data meta-analysis (IPD-MA) offers a unique opportunity to develop and validate a universal prediction model to help choose the optimal gonadotropin starting dose to minimize treatment risks without affecting efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE AND RATIONALE<\/jats:title>\n                    <jats:p>The objective of this IPD-MA is to develop and validate a gonadotropin dose-selection model to guide the choice of a gonadotropin starting dose in IVF\/ICSI, with the purpose of minimizing treatment risks without compromising live birth rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SEARCH METHODS<\/jats:title>\n                    <jats:p>Electronic databases including MEDLINE, EMBASE, and CRSO were searched to identify eligible studies. The last search was performed on 13 July 2022. Randomized controlled trials (RCTs) were included if they compared different doses of gonadotropins in women undergoing IVF\/ICSI, presented at least one type of ORT, and reported on live birth or ongoing pregnancy. Authors of eligible studies were contacted to share their individual participant data (IPD). IPD and information within publications were used to determine the risk of bias. Generalized linear mixed multilevel models were applied for predictor selection and model development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OUTCOMES<\/jats:title>\n                    <jats:p>A total of 14 RCTs with data of 3455 participants were included. After extensive modeling, women aged 39\u2009years and over were excluded, which resulted in the definitive inclusion of 2907 women. The optimal prediction model for live birth included six predictors: age, gonadotropin starting dose, body mass index, AFC, IVF\/ICSI, and AMH. This model had an area under the curve (AUC) of 0.557 (95% confidence interval (CI) from 0.536 to 0.577). The clinically feasible live birth model included age, starting dose, and AMH and had an AUC of 0.554 (95% CI from 0.530 to 0.578). Two models were selected as the optimal model for combined treatment risk, as their performance was equal. One included age, starting dose, AMH, and bFSH; the other also included gonadotropin-releasing hormone (GnRH) analog. The AUCs for both models were 0.769 (95% CI from 0.729 to 0.809). The clinically feasible model for combined treatment risk included age, starting dose, AMH, and GnRH analog, and had an AUC of 0.748 (95% CI from 0.709 to 0.787).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS<\/jats:title>\n                    <jats:p>The aim of this study was to create a model including patient characteristics whereby gonadotropin starting dose was predictive of both live birth and treatment risks. The model performed poorly on predicting live birth by modifying the\u00a0FSH starting dose. On the contrary, predicting treatment risks in terms of OHSS occurrence and management by modifying the\u00a0gonadotropin starting dose was adequate. This dose-selection model, consisting of easily obtainable patient characteristics, aids in the choice of the optimal gonadotropin starting dose for each individual patient to lower treatment risks and potentially reduce treatment costs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/humupd\/dmae032","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T16:17:32Z","timestamp":1730477852000},"page":"116-132","source":"Crossref","is-referenced-by-count":19,"title":["Development and validation of a gonadotropin dose selection model for optimized ovarian stimulation in IVF\/ICSI: an individual participant data meta-analysis"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1709-5611","authenticated-orcid":false,"given":"Nienke","family":"Schouten","sequence":"first","affiliation":[{"name":"Division Woman and Baby, Reproductive Medicine, University Medical Center Utrecht, University of Utrecht , Utrecht, The","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-8134","authenticated-orcid":false,"given":"Rui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Monash Medical Centre, Monash University , Clayton, VIC,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Torrance","sequence":"additional","affiliation":[{"name":"Division Woman and Baby, Reproductive Medicine, University Medical Center Utrecht, University of Utrecht , Utrecht, The","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Van Tilborg","sequence":"additional","affiliation":[{"name":"Division Woman and Baby, Reproductive Medicine, University Medical Center Utrecht, University of Utrecht , Utrecht, The","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0810-6195","authenticated-orcid":false,"given":"Ercan","family":"Bastu","sequence":"additional","affiliation":[{"name":"Acibadem University Faculty of Medicine, Department of Obstetrics and Gynecology, Istanbul University School of Medicine , Istanbul,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6049-7731","authenticated-orcid":false,"given":"Christina","family":"Bergh","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg University , Gothenburg,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2373-8257","authenticated-orcid":false,"given":"Thomas","family":"D\u2019Hooghe","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Research and Development, Merck Healthcare KGaA , Darmstadt,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5619-1809","authenticated-orcid":false,"given":"Jesper","family":"Friis Petersen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, North Zealand Hospital , Hilleroed,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannamannadiar","family":"Jayaprakasan","sequence":"additional","affiliation":[{"name":"Royal Derby Hospital, Derby & University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5642-7367","authenticated-orcid":false,"given":"Yacoub","family":"Khalaf","sequence":"additional","affiliation":[{"name":"Assisted Conception Unit, Guy\u2019s & St Thomas\u2019s Hospital , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Klinkert","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynaecology, University Medical Center Groningen , Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-9547","authenticated-orcid":false,"given":"Antonio","family":"La Marca","sequence":"additional","affiliation":[{"name":"Department of Obstetrics Gynaecology and Paediatric Sciences, University of Modena and Reggio Emilia , Modena,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6529-6912","authenticated-orcid":false,"given":"Lan","family":"Vuong","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Medicine and Pharmacy at Ho Chi Minh City , Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-870X","authenticated-orcid":false,"given":"Louise","family":"Lapens\u00e9e","sequence":"additional","affiliation":[{"name":"Reproductive Endocrinology and Infertility, Clinique ovo , Montr\u00e9al,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1694-1142","authenticated-orcid":false,"given":"Sarah","family":"Lensen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Royal Women\u2019s Hospital, University of Melbourne , Melbourne, Victoria,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2548-1114","authenticated-orcid":false,"given":"\u00c5sa","family":"Magnusson","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg University , Gothenburg,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9942-7810","authenticated-orcid":false,"given":"Adolfo","family":"Allegra","sequence":"additional","affiliation":[{"name":"Reproductive Medicine Unit, ANDROS Day Surgery Clinic , Palermo,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Nyboe Andersen","sequence":"additional","affiliation":[{"name":"The Fertility Department, Copenhagen University Hospital, Rigshospitalet , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1385-1966","authenticated-orcid":false,"given":"Simone","family":"Oudshoorn","sequence":"additional","affiliation":[{"name":"Division Woman and Baby, Reproductive Medicine, University Medical Center Utrecht, University of Utrecht , Utrecht, The","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"Popovic-Todorovic","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Universitair Ziekenhuis Brussel , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8337-550X","authenticated-orcid":false,"given":"Ben Willem","family":"Mol","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Monash Medical Centre, Monash University , Clayton, VIC,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9400-0615","authenticated-orcid":false,"given":"Marinus","family":"Eijkemans","sequence":"additional","affiliation":[{"name":"Division Woman and Baby, Reproductive Medicine, University Medical Center Utrecht, University of Utrecht , Utrecht, The","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1366-2727","authenticated-orcid":false,"given":"Frank","family":"Broekmans","sequence":"additional","affiliation":[{"name":"Division Woman and Baby, Reproductive Medicine, University Medical Center Utrecht, University of Utrecht , Utrecht, The","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"2025030423085214300_dmae032-B1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.rbmo.2017.01.012","article-title":"A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF\/ICSI cycles","volume":"34","author":"Allegra","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"2025030423085214300_dmae032-B2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Andersen","year":"2017","journal-title":"Fertil Steril"},{"key":"2025030423085214300_dmae032-B3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejogrb.2016.05.027","article-title":"A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response","volume":"203","author":"Bastu","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2025030423085214300_dmae032-B4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1472-6483(10)60200-3","article-title":"Complications related to ovarian stimulation and oocyte retrieval in 4052 oocyte donor cycles","volume":"17","author":"Bodri","year":"2008","journal-title":"Reprod Biomed Online"},{"key":"2025030423085214300_dmae032-B5","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/humrep\/deq080","article-title":"Maternal death related to IVF in the Netherlands 1984\u20132008","volume":"25","author":"Braat","year":"2010","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1471-0528.1995.tb10840.x","article-title":"Diagnosis, prevention and management of ovarian hyperstimulation syndrome","volume":"102","author":"Brinsden","year":"1995","journal-title":"Br J Obstet Gynaecol"},{"key":"2025030423085214300_dmae032-B7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10815-011-9704-8","article-title":"Empty follicle syndrome after GnRHa triggering versus hCG triggering in COS","volume":"29","author":"Castillo","year":"2012","journal-title":"J Assist Reprod Genet"},{"key":"2025030423085214300_dmae032-B4367734","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.fertnstert.2016.06.013","article-title":"Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response","volume":"106","author":"Chang","year":"2016","journal-title":"Fertility and Sterility"},{"key":"2025030423085214300_dmae032-B88053428","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/humrep\/des049","article-title":"Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol","volume":"27","author":"Chen","year":"2012","journal-title":"Human Reproduction"},{"key":"2025030423085214300_dmae032-B8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mce.2011.04.018","article-title":"GnRH receptor mutations in isolated gonadotropic deficiency","volume":"346","author":"Chevrier","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"2025030423085214300_dmae032-B9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3109\/14647273.2015.1071500","article-title":"Rescue hCG to treat empty follicle syndrome after the use of a GnRH agonist as oocyte maturation trigger: first report on fresh embryo transfer and clinical pregnancy","volume":"18","author":"Christopoulos","year":"2015","journal-title":"Hum Fertil (Camb)"},{"key":"2025030423085214300_dmae032-B10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S1472-6483(10)60040-5","article-title":"Epidemiology of OHSS","volume":"19","author":"Delvigne","year":"2009","journal-title":"Reprod Biomed Online"},{"key":"2025030423085214300_dmae032-B11","first-page":"2010","article-title":"Cumulative live birth rates and number of oocytes retrieved in women of advanced age. A single centre analysis including 4500 women\u2265 38 years old","volume":"33","author":"Devesa","year":"2018","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B12","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/humrep\/der251","article-title":"An OHSS-Free Clinic by segmentation of IVF treatment","volume":"26","author":"Devroey","year":"2011","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B13","first-page":"370","article-title":"Conventional ovarian stimulation and single embryo transfer for IVF\/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?","volume":"31","author":"Drakopoulos","year":"2016","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B14","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/humrep\/deaa242","article-title":"Top 10 priorities for future infertility research: an international consensus development study","volume":"35","author":"Duffy","year":"2020","journal-title":"Human Reproduction"},{"key":"2025030423085214300_dmae032-B15","author":"FDA","year":"2019"},{"key":"2025030423085214300_dmae032-B16","doi-asserted-by":"crossref","first-page":"hoz003","DOI":"10.1093\/hropen\/hoz003","article-title":"A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF","volume":"2019","author":"Friis Petersen","year":"2019","journal-title":"Hum Reprod Open"},{"key":"2025030423085214300_dmae032-B17","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0","author":"Higgins","year":"2017"},{"key":"2025030423085214300_dmae032-B18","doi-asserted-by":"crossref","DOI":"10.1002\/9781118548387","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"2013"},{"key":"2025030423085214300_dmae032-B19","author":"Into Maternal CE","year":"2007"},{"key":"2025030423085214300_dmae032-B20","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.rbmo.2021.01.023","article-title":"Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF\/ICSI patients: a randomized controlled trial","volume":"42","author":"Ishihara","year":"2021","journal-title":"Reprod Biomed Online"},{"key":"2025030423085214300_dmae032-B21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/rmb2.12307","article-title":"Assisted reproductive technology in Japan: a summary report for 2017 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology","volume":"19","author":"Ishihara","year":"2020","journal-title":"Reprod Med Biol"},{"key":"2025030423085214300_dmae032-B22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/humrep\/deab126.023","article-title":"Improved safety and efficiency of individualised versus conventional gonadotropin dosing for ovarian stimulation in IVF\/ICSI: an individual patient meta-analysis (IPD-MA)","volume":"36","author":"Janse","year":"2021","journal-title":"Human Reproduction"},{"key":"2025030423085214300_dmae032-B251","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1471-0528.2010.02545.x","article-title":"A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count: fertility and assisted reproduction","volume":"117","author":"Jayaprakasan","year":"2010","journal-title":"BJOG An Int J Obstet Gynaecol"},{"key":"2025030423085214300_dmae032-B23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.fertnstert.2012.05.042","article-title":"Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women","volume":"98","author":"Jayaprakasan","year":"2012","journal-title":"Fertil Steril"},{"key":"2025030423085214300_dmae032-B24","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1093\/humrep\/det303","article-title":"The optimum number of oocytes in IVF treatment: an analysis of 2455 cycles in China","volume":"28","author":"Ji","year":"2013","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B25","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/humrep\/deh663","article-title":"Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial","volume":"20","author":"Klinkert","year":"2005","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B26","author":"Klinkert"},{"key":"2025030423085214300_dmae032-B27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/humrep\/des361","article-title":"Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger","volume":"28","author":"Kummer","year":"2013","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.rbmo.2020.09.001","article-title":"Incidences and risk factors of moderate-to-severe ovarian hyperstimulation syndrome and severe hemoperitoneum in 1,435,108 oocyte retrievals","volume":"42","author":"Kuroda","year":"2021","journal-title":"Reprod Biomed Online"},{"key":"2025030423085214300_dmae032-B29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1757-2215-6-11","article-title":"Individualization of the FSH starting dose in IVF\/ICSI cycles using the antral follicle count","volume":"6","author":"La Marca","year":"2013","journal-title":"J Ovarian Res"},{"key":"2025030423085214300_dmae032-B30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/humupd\/dmt037","article-title":"Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice","volume":"20","author":"La Marca","year":"2014","journal-title":"Hum Reprod Update"},{"key":"2025030423085214300_dmae032-B31","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.rbmo.2013.07.008","article-title":"Anti-M\u00fcllerian hormone versus antral follicle count for defining the starting dose of FSH","volume":"27","author":"Lan","year":"2013","journal-title":"Reprod Biomed Online"},{"key":"2025030423085214300_dmae032-B32","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/humrep\/dez100","article-title":"The number of oocytes associated with maximum cumulative live birth rates per aspiration depends on female age: a population study of 221 221 treatment cycles","volume":"34","author":"Law","year":"2019","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B33","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.fertnstert.2015.08.014","article-title":"450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial","volume":"104","author":"Lefebvre","year":"2015","journal-title":"Fertil Steril"},{"key":"2025030423085214300_dmae032-B34","first-page":"CD012693","article-title":"Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF\/ICSI)","volume":"1","author":"Lensen","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2025030423085214300_dmae032-B35","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/humrep\/deac113","article-title":"Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial","volume":"37","author":"Liu","year":"2022","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/humrep\/dex334","article-title":"The number of oocytes retrieved during IVF: a balance between efficacy and safety","volume":"33","author":"Magnusson","year":"2018","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B37","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/humrep\/dex012","article-title":"The addition of anti-M\u00fcllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response\u2014a randomized, controlled trial","volume":"32","author":"Magnusson","year":"2017","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B38","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.fertnstert.2015.06.011","article-title":"Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles","volume":"104","author":"Meyer","year":"2015","journal-title":"Fertil Steril"},{"key":"2025030423085214300_dmae032-B39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/humupd\/dmz037","article-title":"Ovarian stimulation for freeze-all IVF cycles: a systematic review","volume":"26","author":"Mizrachi","year":"2020","journal-title":"Hum Reprod Update"},{"key":"2025030423085214300_dmae032-B40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012103.pub2","article-title":"Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews","volume":"2017","author":"Mourad","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"2025030423085214300_dmae032-B41","doi-asserted-by":"crossref","first-page":"102307","DOI":"10.1016\/j.bpobgyn.2022.102307","article-title":"Association between the number of oocytes and cumulative live birth rate: a systematic review","volume":"87","author":"Neves","year":"2023","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2025030423085214300_dmae032-B42","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.rbmo.2014.11.013","article-title":"Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alpha","volume":"30","author":"Olivennes","year":"2015","journal-title":"Reprod Biomed Online"},{"key":"2025030423085214300_dmae032-B43","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1093\/humrep\/dex319","article-title":"Individualized versus standard FSH dosing in women starting IVF\/ICSI: an RCT. Part 2: The predicted hyper responder","volume":"32","author":"Oudshoorn","year":"2017","journal-title":"Human Reproduction"},{"key":"2025030423085214300_dmae032-B44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.fertnstert.2005.07.1292","article-title":"Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles","volume":"85","author":"Papanikolaou","year":"2006","journal-title":"Fertil Steril"},{"key":"2025030423085214300_dmae032-B45","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.fertnstert.2018.04.039","article-title":"Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization\/intracytoplasmic sperm injection: a multicenter multinational analysis including\u223c 15,000 women","volume":"110","author":"Polyzos","year":"2018","journal-title":"Fertil Steril"},{"key":"2025030423085214300_dmae032-B46","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/humrep\/deg181","article-title":"A prospective study of predictive factors of ovarian response in \u2018standard\u2019IVF\/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram","volume":"18","author":"Popovic-Todorovic","year":"2003","journal-title":"Human Reproduction"},{"key":"2025030423085214300_dmae032-B47","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1093\/humrep\/deab155","article-title":"A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF\/ICSI patients","volume":"36","author":"Qiao","year":"2021","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/humrep\/dez258","article-title":"A systematic review of the quality of clinical prediction models in in vitro fertilisation","volume":"35","author":"Ratna","year":"2020","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B49","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.rbmo.2017.04.012","article-title":"Empty follicle syndrome revisited: definition, incidence, aetiology, early diagnosis and treatment","volume":"35","author":"Revelli","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"2025030423085214300_dmae032-B50","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/sim.8516","article-title":"Individual participant data meta-analysis to examine interactions between treatment effect and participant-level covariates: Statistical recommendations for conduct and planning","volume":"39","author":"Riley","year":"2020","journal-title":"Stat Med"},{"key":"2025030423085214300_dmae032-B51","author":"Samson","year":"2012"},{"key":"2025030423085214300_dmae032-B52","doi-asserted-by":"crossref","first-page":"deac104010","DOI":"10.1093\/humrep\/deac104.010","article-title":"O-010 the one-and-done approach: does higher dosing of gonadotropins in predicted high and low responders increase the incidence of multiple live births from one ART-stimulation cycle?","volume":"37","author":"Schouten","year":"2022","journal-title":"Human Reproduction"},{"key":"2025030423085214300_dmae032-B53","doi-asserted-by":"crossref","first-page":"dead093.1017","DOI":"10.1093\/humrep\/dead093.1017","article-title":"693 Retrospective evaluation of the effect of the implementation of the DIVINE dose-calculator in daily practice on ovarian hyperstimulation treatment risk and live birth rate","volume":"38","author":"Schouten","year":"2023","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B54","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/humupd\/dmq041","article-title":"Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis","volume":"17","author":"Sterrenburg","year":"2011","journal-title":"Hum Reprod Update"},{"key":"2025030423085214300_dmae032-B55","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.fertnstert.2013.12.026","article-title":"Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles","volume":"101","author":"Steward","year":"2014","journal-title":"Fertil Steril"},{"key":"2025030423085214300_dmae032-B56","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"2025030423085214300_dmae032-B57","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/humrep\/der106","article-title":"Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles","volume":"26","author":"Sunkara","year":"2011","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B58","article-title":"P-198 A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF\/ICSI treatment","volume":"25","author":"Tasker","year":"2010","journal-title":"Human Reproduction"},{"key":"2025030423085214300_dmae032-B59","doi-asserted-by":"crossref","first-page":"hoaa067","DOI":"10.1093\/hropen\/hoaa067","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI","volume":"2020","author":"TEGG Ovarian Stimulation","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2025030423085214300_dmae032-B60","doi-asserted-by":"crossref","first-page":"hoaa032","DOI":"10.1093\/hropen\/hoaa032","article-title":"ART in Europe, 2016: results generated from European registries by ESHRE","volume":"2020","author":"Wyns","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2025030423085214300_dmae032-B61","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/humrep\/dew051","article-title":"Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF\/ICSI cycles","volume":"31","author":"Toftager","year":"2016","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B62","article-title":"Annual incidence of severe ovarian hyperstimulation syndrome","volume":"68","author":"Tom\u00e1s","year":"2021","journal-title":"Dan Med J"},{"key":"2025030423085214300_dmae032-B63","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","article-title":"Calibration: the Achilles heel of predictive analytics","volume":"17","author":"Van Calster","year":"2019","journal-title":"BMC Med"},{"key":"2025030423085214300_dmae032-B64","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1472-6483(10)60633-5","article-title":"Optimum number of oocytes for a successful first IVF treatment cycle","volume":"13","author":"Van der Gaast","year":"2006","journal-title":"Reprod Biomed Online"},{"key":"2025030423085214300_dmae032-B65","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/humrep\/dex318","article-title":"Individualized versus standard FSH dosing in women starting IVF\/ICSI: an RCT. Part 1: The predicted poor responder","volume":"32","author":"Van Tilborg","year":"2017","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B66","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.fertnstert.2016.10.037","article-title":"How many oocytes are optimal to achieve multiple live births with one stimulation cycle? The one-and-done approach","volume":"107","author":"Vaughan","year":"2017","journal-title":"Fertil Steril"},{"key":"2025030423085214300_dmae032-B67","first-page":"112","article-title":"A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial","volume":"32","author":"Youssef","year":"2017","journal-title":"Hum Reprod"},{"key":"2025030423085214300_dmae032-B68","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/oxfordjournals.humrep.a136281","article-title":"The empty follicle syndrome: a pharmaceutical industry syndrome","volume":"10","author":"Zegers-Hochschild","year":"1995","journal-title":"Hum Reprod"}],"container-title":["Human Reproduction Update"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humupd\/article-pdf\/31\/2\/116\/61250443\/dmae032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humupd\/article-pdf\/31\/2\/116\/61250443\/dmae032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T18:10:08Z","timestamp":1741111808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humupd\/article\/31\/2\/116\/7929953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":71,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,12,20]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humupd\/dmae032","relation":{},"ISSN":["1355-4786","1460-2369"],"issn-type":[{"value":"1355-4786","type":"print"},{"value":"1460-2369","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,12,20]]}}}